Development of a method to detect very low levels of HER2 expression in Circulating Tumor Cells (CTCs) by liquid biopsy in patients with metastatic breast cancer

被引:0
|
作者
Di Caro, Giuseppe
Bourdon, David
Kunihiro, Andrew
Cunsolo, Alessandra
Lam, Ernest
Slade, Megan
Blankfard, Martin
Schwartzberg, Lee
机构
关键词
D O I
10.1158/1538-7445.SABCS23-PO5-04-04
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PO5-04-04
引用
收藏
页数:3
相关论文
共 50 条
  • [41] Distribution and prognostic role of HER2 status of circulating tumor cells (CTCs) and tumor-derived extracellular vesicles (tdEVs) in HER2-metastatic breast cancer (MBC) patients (pts)
    Nicolo, E.
    Munoz-Arcos, L.
    D'Amico, P.
    Zhang, Y.
    Gerratana, L.
    Serafini, M.
    Pontolillo, L.
    Strickland, K.
    Manai, M.
    Davis, A. A.
    Donahue, J.
    Liu, H.
    Gradishar, W. J.
    Shah, A. N.
    Curigliano, G.
    Reduzzi, C.
    Cristofanilli, M.
    ANNALS OF ONCOLOGY, 2023, 34 : S363 - S363
  • [42] Quantitative Assessment of Her-2 Expression of Circulating Tumor Cells in Patients with Metastatic and Non Metastatic Breast Cancer
    Bidard, F. C.
    Ligthart, S. T.
    Pierga, J. Y.
    Terstappen, L. W. M. M.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S124 - S125
  • [43] Prognostic Impact of HER2 and ER Status of Circulating Tumor Cells in Metastatic Breast Cancer Patients with a HER2-Negative Primary Tumor
    Beije, Nick
    Onstenk, Wendy
    Kraan, Jaco
    Sieuwerts, Anieta M.
    Hamberg, Paul
    Dirix, Luc Y.
    Brouwer, Anja
    de Jongh, Felix E.
    Jager, Agnes
    Seynaeve, Caroline M.
    Van, Ngoc M.
    Foekens, John A.
    Martens, John W. M.
    Sleijfer, Stefan
    NEOPLASIA, 2016, 18 (11): : 647 - 653
  • [44] Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
    Bates, M.
    Sperinde, J.
    Koestler, W. J.
    Ali, S. M.
    Leitzel, K.
    Fuchs, E. M.
    Paquet, A.
    Lie, Y.
    Sherwood, T.
    Horvat, R.
    Singer, C. F.
    Winslow, J.
    Weidler, J. M.
    Huang, W.
    Lipton, A.
    ANNALS OF ONCOLOGY, 2011, 22 (09) : 2014 - 2020
  • [45] Identification of a subpopulation of metastatic breast cancer patients with very high HER2 expression levels and possible resistance to trastuzumab
    Sperinde, J.
    Ali, S.
    Leitzel, K.
    Fuchs, E.
    Koestler, W. J.
    Paquet, A.
    Weidler, J.
    Huang, W.
    Bates, M.
    Lipton, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [46] Successful targeting HER2 in heavily pretreated HER2-negative metastatic breast cancer patients presenting with elevated serum levels of the HER2 extracellular domain and/or HER2 overexpressing circulating tumor cells
    Kurbacher, C. M.
    Quade, A.
    Eichler, C.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. R.
    CANCER RESEARCH, 2016, 76
  • [47] Isolation and expression profiling of circulating tumor cells (CTCs) in breast cancer patients
    Lang, JE
    Scott, JH
    Haqq, CM
    Ginzinger, D
    Esserman, LJ
    Park, JW
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S225 - S225
  • [48] Apoptosis in Circulating Tumor Cells (CTCs) of Early and Metastatic Breast Cancer Patients.
    Kallergi, G.
    Konstantinidis, G.
    Papadaki, M.
    Agelaki, S.
    Mavroudis, D.
    Stournaras, C.
    Georgoulias, V.
    CANCER RESEARCH, 2011, 71
  • [49] Targeting HER2 in patients with HER2-negative metastatic breast cancer with elevated serum levels of the HER2 extracellular domain and/or HER2-positive circulating tumor cells in the clinical routine
    Kurbacher, C. M.
    Quade, A.
    Kunstmann, G.
    Herz, S.
    Kurbacher, J. A.
    Warm, M. A.
    ANNALS OF ONCOLOGY, 2015, 26
  • [50] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40